# Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

> **NCT05420077** · PHASE1 · TERMINATED · sponsor: **RVAC Medicines (US), Inc.** · enrollment: 13 (actual)

## Conditions studied

- Infectious Disease
- COVID-19

## Interventions

- **BIOLOGICAL:** RVM-V001 10 µg
- **BIOLOGICAL:** RVM-V001 30 µg
- **BIOLOGICAL:** RVM-V001 60 µg

## Key facts

- **NCT ID:** NCT05420077
- **Lead sponsor:** RVAC Medicines (US), Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-12
- **Primary completion:** 2023-06-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The landscape of the study area changed, making it impossible to continue the study.
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420077, "Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05420077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*